Customized Animal Models of IBD

Inflammatory bowel disease (IBD) is a chronic intestinal inflammatory condition that affects millions of people worldwide. The combined effects of genetic, immunological, environmental, and microbial factors render it difficult to determine the specific mechanism underlying the induction and perpetuation of IBD. In addition, numerous treatments have been evaluated, but few have reached the clinic. Various animal models of IBD have contributed enormously to the understanding of IBD pathogenesis in terms of genomics, transcriptomics, proteomics, microbiome, and drug development of novel therapies.

Our Well-Established Animal Models of IBD

At Ace Therapeutics, we recognize the importance of using reliable and accurate animal models to advance your understanding of IBD and develop novel therapies. These models allow us help clients evaluate novel drugs and therapies and provide valuable insight into disease mechanisms and potential treatment options.

Chemical-Induced IBD Models

Ace Therapeutics offers a wide range of customized chemical-induced IBD models to help clients properly understand the histopathological and morphological changes in the gut, develop novel therapeutic agents for the treatment of IBD, and dissect the possible mechanisms of action of specific drugs.

The different models in this category have their own specific uses due to the different methods of disease induction. Our experts can guide you in selecting the appropriate models depending on your therapeutic target, resulting in data that accurately represents human IBD.

T Cell Transfer Models of IBD

Ace Therapeutics offers Customized CD4⁺CD45RB^high T cell transfer models of colitis to accelerate clients' preclinical IBD studies. Adoptive transfer of naive T cells (CD4⁺CD45RB^high) into immune deficient Rag -/- mice. It usually takes around 6–8 weeks, depending on the microbial populations present in the animal facility, to develop severe disease manifested by hunching, progressive weight loss, and diarrhoea.

Anti-CD40-Induced Colitis Models

We provide reliable animal models of anti-cd40-induced colitis to pharmaceutical, biotech, and academic clients around the world. Colitis is induced via administration of an agonistic CD40 monoclonal antibody to T and B cell-deficient C57BL/6 RAG2-/- or CB-17 SCID mice. Naïve RAG2-/- or CB-17 SCID mice inject with PBS in lieu of anti-CD40 antibodies are used as a negative control for colitis.

Spontaneous Gene Mutation Models of IBD

Ace Therapeutics offers spontaneous gene mutation models of Crohn's disease (CD)-like ileitis to help clients further understand the role of genetics, mucosal immunity, leukocyte trafficking, cytokine biology, and epithelial barrier function in the pathogenesis of chronic intestinal inflammation and to develop therapeutic strategies for CD.

SAMP1/YitFc Model of Colitis
C3H/HeJBir (C3Bir) Model of Colitis

Genetically Engineered Models of IBD

Our team of experts has extensive experience in developing genetically engineered animal models and IBD research, providing clients with high-quality genetically engineered mouse models to aid in IBD pathogenesis research and the development of new therapies.

IL-10 Knockout Models
Mdr1a Knockout Models

Bacteria-Induced Models of IBD

Citrobacter rodentium is a natural mouse Gram-negative pathogenic bacterium with genetic properties and virulence factors that evoke an inflammatory response similar to that induced in humans by enteropathogenic Escherichia coli (EPEC). The team at Ace Therapeutics has extensive experience with preclinical animal models of colitis and provides reliable Citrobacter rodentium-induced colitis models to help clients study the pathogenesis of enteric infection-induced inflammation.

Study Endpoints

We offer a variety of endpoint analyses to help clients validate animal models of IBD and evaluate the efficacy of novel therapeutics. You have the flexibility to analyze only a few animal samples, select specific groups of animals for analysis, or even skip the analysis altogether if the results are unsatisfactory. Our scientists will review your preliminary results with you and can recommend the best analyses to accelerate your IBD research program.

Weight loss & disease activity index (DAI)
In-life endoscopy
Colon weight & length
Colon and plasma/serum cytokines
Fecal lipocalin (LCN2), calprotectin, & myeloperoxidase (MPO)
Peripheral lymphoid organ immunophenotyping (Flow cytometry)
Colon lamina propria immunophenotyping (Flow cytometry)
Customized assays and endpoints

Applications of Our Animal Models of IBD

Study IBD pathomechanism
Evaluate preclinical efficacy
Evaluate pharmacokinetics (PK)
Drug safety testing
Biomarker studies

Improve the translation of your IBD research with Ace Therapeutics' IBD animal models and associated endpoint assays. Our experts can guide you in selecting the right model based on your therapeutic goals, resulting in data that accurately represents human IBD. Contact us for a quote.

! For research use only, not intended for any clinical use.